Dr. Reddy’s Laboratories received FDA approval for its testosterone transdermal generic, a move that positions the company to expand its market share in the competitive hormone replacement therapy sector. This approval is expected to bolster the company's revenue by offering a cost-effective alternative to branded testosterone treatments for patients with hypogonadism.